BMC medicine · 2025
Normobaric hyperoxia for intracerebral hemorrhage: a randomized clinical trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Zhiying, Ding Jiayue, Bao Bing, Wu Moxin, Cao Xianming, Li Weili, Wu Xiangbin, Xia Zhongbin, Xiang Yuanyuan, Chen Liang, Liu Hao, Ji Xunming, Yin Xiaoping, Meng Ran
Аннотация
BACKGROUND: Intracerebral hemorrhage (ICH) is a challenging and life-threatening stroke subtype. Normobaric hyperoxia (NBO) is a promising therapeutic strategy for ICH. Herein, we evaluated the safety and efficacy of NBO in patients with ICH.
METHODS: In this randomized, controlled, two-arm (1:1 ratio), open-label clinical trial, participants were randomly assigned to either the NBO group (100% O2 at 8 L/min for 1 h per session, four times daily, for 7 days) or the control group (100% O2 at 2 L/min continuously for 24 h daily for 7 days). The primary outcome was the proportion of patients achieving a modified Rankin Scale (mRS) score of 0-3 at 90 days. The results are presented as the risk ratio (RR) with 95% confidence intervals (95% CI). P < .05 indicated statistical significance.
RESULTS: A total of 96 patients were enrolled (NBO, n = 48; control, n = 48). The proportion of patients who achieved an mRS score of 0-3 at 90 days was significantly higher in the NBO group than in the control group (81.3% vs. 56.3%; unadjusted RR, 1.44; 95% CI, 1.09-1.92; unadjusted P = .01; adjusted RR, 1.39; 95% CI, 1.06 to 1.82; adjusted P = .02). Additionally, the 90-day Barthel Index scores on days 7 and 14 were significantly higher in the NBO group (all P < .05). Imaging assessments revealed that both absolute and relative perihematomal edema at 7 and 14 days were reduced in the NBO group, and perfusion in the region surrounding the hematoma was improved at 7 days compared to that in the control group (all P < .05). No significant differences in oxygen-related complications were observed between the two groups (all P > .05).
CONCLUSIONS: Early intermittent administration of NBO in patients with ICH may improve 90-day outcomes without increasing the risk of death or other oxygen-related complications.
TRIAL REGISTRATION: NCT04144868.
METHODS: In this randomized, controlled, two-arm (1:1 ratio), open-label clinical trial, participants were randomly assigned to either the NBO group (100% O2 at 8 L/min for 1 h per session, four times daily, for 7 days) or the control group (100% O2 at 2 L/min continuously for 24 h daily for 7 days). The primary outcome was the proportion of patients achieving a modified Rankin Scale (mRS) score of 0-3 at 90 days. The results are presented as the risk ratio (RR) with 95% confidence intervals (95% CI). P < .05 indicated statistical significance.
RESULTS: A total of 96 patients were enrolled (NBO, n = 48; control, n = 48). The proportion of patients who achieved an mRS score of 0-3 at 90 days was significantly higher in the NBO group than in the control group (81.3% vs. 56.3%; unadjusted RR, 1.44; 95% CI, 1.09-1.92; unadjusted P = .01; adjusted RR, 1.39; 95% CI, 1.06 to 1.82; adjusted P = .02). Additionally, the 90-day Barthel Index scores on days 7 and 14 were significantly higher in the NBO group (all P < .05). Imaging assessments revealed that both absolute and relative perihematomal edema at 7 and 14 days were reduced in the NBO group, and perfusion in the region surrounding the hematoma was improved at 7 days compared to that in the control group (all P < .05). No significant differences in oxygen-related complications were observed between the two groups (all P > .05).
CONCLUSIONS: Early intermittent administration of NBO in patients with ICH may improve 90-day outcomes without increasing the risk of death or other oxygen-related complications.
TRIAL REGISTRATION: NCT04144868.